{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:32:10Z","timestamp":1791765130136,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"DOI":"10.1007\/s11934-026-01330-7","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:02:09Z","timestamp":1775887329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unequal Access to Novel Systemic Therapies for Bladder Cancer: A Global Analysis of Clinical Trials of Immune Checkpoint Inhibitors and Antibody-Drug Conjugates"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-7565","authenticated-orcid":false,"given":"Juan Carlos","family":"Angulo-Lozano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6983-9116","authenticated-orcid":false,"given":"Alejandro","family":"Calvillo-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Noyola-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Cojuc-Konigsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Vaquera-Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Anceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Suzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa F.","family":"Sanchez-Musi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia F. Mendoza Sanchez","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Pichardo-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Badin-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parwiz","family":"Abrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Scherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"3","key":"1330_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","volume":"34","author":"AV Balar","year":"2023","unstructured":"Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023;34(3):289\u201399.","journal-title":"Ann Oncol"},{"issue":"7","key":"1330_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, Matsubara N, G\u00e9czi L, Cheng SYS, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931\u201345.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1330_CR3","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125\u201335.","journal-title":"N Engl J Med"},{"issue":"22","key":"1330_CR4","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fl\u00e9chon A, et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol. 2021;39(22):2474\u201385.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1330_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol. 2023;41(1):22\u201331.","journal-title":"J Clin Oncol"},{"key":"1330_CR6","unstructured":"O\u2019Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023."},{"issue":"10236","key":"1330_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547\u201357.","journal-title":"Lancet"},{"issue":"4","key":"1330_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/CAD.0000000000001449","volume":"34","author":"L Wang","year":"2023","unstructured":"Wang L, Shi G, Zhao G, He W, Cen Z, Xu F. Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis. Anticancer Drugs. 2023;34(4):473\u20138.","journal-title":"Anticancer Drugs"},{"key":"1330_CR9","doi-asserted-by":"publisher","first-page":"175628722098019","DOI":"10.1177\/1756287220980192","volume":"12","author":"M Alt","year":"2020","unstructured":"Alt M, Stecca C, Tobin S, Jiang DM, Sridhar SS. Enfortumab Vedotin in urothelial cancer. Ther Adv Urol. 2020;12:175628722098019.","journal-title":"Ther Adv Urol"},{"issue":"7","key":"1330_CR10","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/annonc\/mdx170","volume":"28","author":"K Chin","year":"2017","unstructured":"Chin K, Chand VK, Nuyten DSA. Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. Ann Oncol. 2017;28(7):1658\u201366.","journal-title":"Ann Oncol"},{"issue":"6suppl","key":"1330_CR11","doi-asserted-by":"publisher","first-page":"TPS582","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS582","volume":"41","author":"AM Kamat","year":"2023","unstructured":"Kamat AM, Steinberg GD, Inman BA, Kates MR, Uchio EM, Porten SP, et al. Study EV-104: Phase 1 study of intravesical Enfortumab Vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)\u2014Trial in progress. J Clin Oncol. 2023;41(6suppl):TPS582\u2013582.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1330_CR12","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1200\/JCO.2023.41.16_suppl.4595","volume":"41","author":"TW Flaig","year":"2023","unstructured":"Flaig TW, Rosenberg JE, Hoimes CJ, O\u2019Donnell PH, Mar N, Gourdin TS, et al. Study EV-103: Neoadjuvant treatment with Enfortumab Vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H. J Clin Oncol. 2023;41(16suppl):4595\u20134595.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1330_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","volume":"31","author":"DE Magee","year":"2020","unstructured":"Magee DE, Hird AE, Klaassen Z, Sridhar SS, Nam RK, Wallis CJD, et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Ann Oncol. 2020;31(1):50\u201360.","journal-title":"Ann Oncol"},{"key":"1330_CR14","first-page":"10","volume":"2023","author":"P Maisch","year":"2023","unstructured":"Maisch P, Hwang EC, Kim K, Narayan VM, Bakker C, Kunath F, et al. Immunotherapy for advanced or metastatic urothelial carcinoma. Cochrane Database Syst Reviews. 2023;2023:10.","journal-title":"Cochrane Database Syst Reviews"},{"key":"1330_CR15","unstructured":"World Bank Country and Lending Groups. \u2013 World Bank Data Help Desk [Internet]. Available: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"issue":"4","key":"1330_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"1330_CR17","doi-asserted-by":"crossref","unstructured":"Shastry M, Gupta A, Chandarlapaty S, Young M, Powles T, Hamilton E. Rise of Antibody-Drug Conjugates: The Present and Future. American Society of Clinical Oncology Educational Book; 2023. (43).","DOI":"10.1200\/EDBK_390094"},{"issue":"35","key":"1330_CR18","doi-asserted-by":"publisher","first-page":"58642","DOI":"10.18632\/oncotarget.17407","volume":"8","author":"C Avellini","year":"2017","unstructured":"Avellini C, Licini C, Lazzarini R, Gesuita R, Guerra E, Tossetta G, et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget. 2017;8(35):58642\u201353.","journal-title":"Oncotarget"},{"key":"1330_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388.","journal-title":"N Engl J Med"},{"issue":"10","key":"1330_CR20","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","volume":"36","author":"TB Powles","year":"2025","unstructured":"Powles TB, Van der Heijden MS, Loriot Y, et al. Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial. Ann Oncol. 2025;36(10):1212\u20139.","journal-title":"Ann Oncol"},{"issue":"6","key":"1330_CR21","doi-asserted-by":"publisher","first-page":"102453","DOI":"10.1016\/j.clgc.2025.102453","volume":"23","author":"P Jain","year":"2025","unstructured":"Jain P, Naqvi SAA, Tripathi N, et al. Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis. Clin Genitourin Cancer. 2025;23(6):102453.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"1330_CR22","first-page":"321","volume":"390","author":"MD Galsky","year":"2024","unstructured":"Galsky MD, Powles T, Balar AV, Sonpavde G, Gupta S, Bellmunt J, et al. Nivolumab plus Gemcitabine and Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2024;390(4):321\u201333.","journal-title":"N Engl J Med"},{"issue":"9","key":"1330_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/fon-2023-0271","volume":"20","author":"GD Steinberg","year":"2024","unstructured":"Steinberg GD, Shore ND, Palou Redorta J, Galsky MD, Bedke J, Ku JH, et al. CREST: phase III study of sasanlimab and Bacillus Calmette-Gu\u00e9rin for patients with Bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer. Future Oncol. 2024;20(9):891\u2013901.","journal-title":"Future Oncol"},{"issue":"1","key":"1330_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12939-018-0748-6","volume":"17","author":"C Alemayehu","year":"2018","unstructured":"Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries\u2014a systematic review. Int J Equity Health. 2018;17(1):37.","journal-title":"Int J Equity Health"},{"issue":"7264","key":"1330_CR25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1136\/bmj.321.7264.827","volume":"321","author":"A Costello","year":"2000","unstructured":"Costello A, Zumla A. Moving to research partnerships in developing countries. BMJ. 2000;321(7264):827\u20139.","journal-title":"BMJ"},{"issue":"6","key":"1330_CR26","doi-asserted-by":"publisher","first-page":"e1001228","DOI":"10.1371\/journal.pmed.1001228","volume":"9","author":"T Lang","year":"2012","unstructured":"Lang T, Siribaddana S. Clinical trials have gone global: is this a good thing? PLoS Med. 2012;9(6):e1001228.","journal-title":"PLoS Med"},{"issue":"11","key":"1330_CR27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrclinonc.2017.100","volume":"14","author":"B Gyawali","year":"2017","unstructured":"Gyawali B, Sullivan R. Economic evaluation of cancer medicines: missing the woods for the trees. Nat Rev Clin Oncol. 2017;14(11):693\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1330_CR28","first-page":"e280","volume":"23","author":"CS Pramesh","year":"2022","unstructured":"Pramesh CS, Badwe RA, Bhoo-Pathy N, et al. Cancer care and research in low- and middle-income countries: a critical review of the current situation and opportunities for improvement. Lancet Oncol. 2022;23(6):e280\u201392.","journal-title":"Lancet Oncol"},{"key":"1330_CR29","volume-title":"Global Report on Effective Access to Health Products 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global Report on Effective Access to Health Products 2023. Geneva: WHO; 2023."},{"issue":"8","key":"1330_CR30","doi-asserted-by":"publisher","first-page":"e2227252","DOI":"10.1001\/jamanetworkopen.2022.27252","volume":"5","author":"F Rubagumya","year":"2022","unstructured":"Rubagumya F, Hopman WM, Gyawali B, et al. Participation of lower- and upper-middle\u2013income countries in oncology clinical trials led by high-income countries. JAMA Netw Open. 2022;5(8):e2227252.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1330_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","volume":"16","author":"CM Booth","year":"2019","unstructured":"Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol. 2019;16(5):312\u201325.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1330_CR32","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1086\/381709","volume":"189","author":"EJ Emanuel","year":"2004","unstructured":"Emanuel EJ, Wendler D, Killen J, Grady C. What makes clinical research in developing countries ethical? J Infect Dis. 2004;189(5):930\u20137.","journal-title":"J Infect Dis"},{"issue":"9919","key":"1330_CR33","first-page":"1415","volume":"383","author":"AA Hyder","year":"2014","unstructured":"Hyder AA, Merritt MW, Ali J, et al. Integrating ethics, equity, and social value in global health research. Lancet. 2014;383(9919):1415\u20136.","journal-title":"Lancet"},{"issue":"2","key":"1330_CR34","first-page":"156","volume":"3","author":"B Gyawali","year":"2017","unstructured":"Gyawali B, Sullivan R. Global access to cancer medicines: moving beyond the 90\u2009\u2212\u200910 gap. J Glob Oncol. 2017;3(2):156\u20138.","journal-title":"J Glob Oncol"},{"key":"1330_CR35","doi-asserted-by":"crossref","unstructured":"Chen Z, Zhong H, Hu HX et al. Chinese innovative drug R&D trends in 2024. Nat Rev Drug Discov. 2024, 0731 (2024).","DOI":"10.1038\/d41573-024-00120-5"},{"issue":"6","key":"1330_CR36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/d41573-025-00068-0","volume":"24","author":"L Tang","year":"2025","unstructured":"Tang L. Analysis of China-to-West pharmaceutical licensing deals in 2024. Nat Rev Drug Discov. 2025;24(6):411\u20132.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1330_CR37","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"1330_CR38","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, et al. NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022;20(8):866\u201378.","journal-title":"J Natl Compr Canc Netw"},{"issue":"15suppl","key":"1330_CR39","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1200\/JCO.2020.38.15_suppl.5047","volume":"38","author":"CJ Hoimes","year":"2020","unstructured":"Hoimes CJ, Adra N, Fleming MT, Kaimakliotis HZ, Picus J, Smith ZL, et al. Phase Ib\/II neoadjuvant (N-) Pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188. J Clin Oncol. 2020;38(15suppl):5047\u20135047.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1330_CR40","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, et al. Randomized phase III KEYNOTE-045 trial of Pembrolizumab versus Paclitaxel, Docetaxel, or Vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970\u20136.","journal-title":"Ann Oncol"},{"issue":"28","key":"1330_CR41","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.21.01003","volume":"39","author":"TL Rose","year":"2021","unstructured":"Rose TL, Harrison MR, Deal AM, Ramalingam S, Whang YE, Brower B, et al. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol. 2021;39(28):3140\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1330_CR42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.euo.2020.02.009","volume":"3","author":"P Grivas","year":"2020","unstructured":"Grivas P, Plimack ER, Balar AV, Castellano D, O\u2019Donnell PH, Bellmunt J, et al. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. Eur Urol Oncol. 2020;3(3):351\u20139.","journal-title":"Eur Urol Oncol"},{"key":"1330_CR43","doi-asserted-by":"crossref","unstructured":"Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP et al. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. J Clin Oncol. 2024.","DOI":"10.1200\/JCO.22.02835"},{"issue":"16","key":"1330_CR44","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.19.03091","volume":"38","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol. 2020;38(16):1797\u2013806.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1330_CR45","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.annonc.2020.09.011","volume":"31","author":"M Bandini","year":"2020","unstructured":"Bandini M, Gibb EA, Gallina A, Raggi D, Marandino L, Bianchi M, et al. Does the administration of preoperative Pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study\u2606. Ann Oncol. 2020;31(12):1755\u201363.","journal-title":"Ann Oncol"},{"issue":"6","key":"1330_CR46","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","volume":"82","author":"K Meghani","year":"2022","unstructured":"Meghani K, Cooley LF, Choy B, Kocherginsky M, Swaminathan S, Munir SS, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Gu\u00e9rin. Eur Urol. 2022;82(6):602\u201310.","journal-title":"Eur Urol"},{"issue":"6suppl","key":"1330_CR47","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1200\/JCO.2023.41.6_suppl.448","volume":"41","author":"J Brown","year":"2023","unstructured":"Brown J, Kaimakliotis HZ, Kelly WK, Ammons V, Picus J, Walling R, et al. HCRN GU14-188: Phase Ib\/II study of neoadjuvant Pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer. J Clin Oncol. 2023;41(6suppl):448\u2013448.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1330_CR48","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1002\/cncr.33067","volume":"126","author":"T Zhang","year":"2020","unstructured":"Zhang T, Harrison MR, O\u2019Donnell PH, Alva AS, Hahn NM, Appleman LJ, et al. A randomized phase 2 trial of Pembrolizumab versus Pembrolizumab and Acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer. 2020;126(20):4485\u201397.","journal-title":"Cancer"},{"issue":"7","key":"1330_CR49","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumigui\u00e9 M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919\u201330.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1330_CR50","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1080\/13696998.2025.2567190","volume":"28","author":"Y Meng","year":"2025","unstructured":"Meng Y, Zhang S, Aout M, et al. Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States. J Med Econ. 2025;28(1):1779\u201397.","journal-title":"J Med Econ"},{"issue":"26","key":"1330_CR51","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti\u2013Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016;34(26):3119\u201325.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1330_CR52","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles T, O\u2019Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. JAMA Oncol. 2017;3(9):e172411.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1330_CR53","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and Durvalumab plus Tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574\u201388.","journal-title":"Lancet Oncol"},{"issue":"10122","key":"1330_CR54","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748\u201357.","journal-title":"Lancet"},{"issue":"11","key":"1330_CR55","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, et al. Gemcitabine and Cisplatin plus Nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2023;29(11):2825\u201334.","journal-title":"Nat Med"},{"issue":"5","key":"1330_CR56","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.euo.2022.02.003","volume":"5","author":"JA Witjes","year":"2022","unstructured":"Witjes JA, Galsky MD, Gschwend JE, Broughton E, Braverman J, Nasroulah F, et al. Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial. Eur Urol Oncol. 2022;5(5):553\u201363.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"1330_CR57","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","volume":"22","author":"EY Yu","year":"2021","unstructured":"Yu EY, Petrylak DP, O\u2019Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. Enfortumab Vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872\u201382.","journal-title":"Lancet Oncol"},{"issue":"16suppl","key":"1330_CR58","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1200\/JCO.2023.41.16_suppl.4566","volume":"41","author":"X Sheng","year":"2023","unstructured":"Sheng X, Zhou L, Yang K, Zhang S, Xu H, Yan X, et al. Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with Toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b\/2 study. J Clin Oncol. 2023;41(16suppl):4566\u20134566.","journal-title":"J Clin Oncol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01330-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-026-01330-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01330-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:02:25Z","timestamp":1775890945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-026-01330-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1007\/s11934-026-01330-7","relation":{},"ISSN":["1534-6285"],"issn-type":[{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies on human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"21"}}